A Velumani, managing director and chief executive of Thyrocare Technologies, said, "When CX Partners invested, we were motivated and ventured into Nueclear, (the in-vivo segment). Now, with NVP's investment, we would explore global markets." NVP manages about $3.7 billion in capital and has funded 500 companies. India's diagnostics sector has been in the radar of PE majors for some time. Early this year, Singapore-based GIC had invested $100 million in Vasan Healthcare, while last year, Goldman Sachs invested about Rs 300 crore for a six per cent stake in Max India. In 2010, US-based TA Associates had invested $35 million in Dr Lal Pathlabs. Last year, PE fund Avigo Capital Partners had acquired 9.27 per cent stake in Super Religare Laboratories for Rs 100 crore.